ÂÜÀòÂÒÂ×

Charlotte McDonagh joined TetraGenetics in April 2020 as SVP, Development and Translational Sciences and has 20 years of experience in the discovery and development of antibody-based therapeutics, including bispecific antibodies and antibody drug conjugates. She was previously VP and Head of Biotherapeutics at Magenta Therapeutics (2017-2020) where she built and led antibody drug conjugate discovery, engineering and CMC activities. Prior to that she held roles of increasing responsibility at Merrimack Pharmaceuticals, where she was VP, Discovery (2015-2016) responsible for multiple early stage programs and Program Leader for a bispecific antibody oncology therapeutic leading the program from lead selection through Phase 2 clinical development (2007-2014). Before joining Merrimack, she was at Seattle Genetics focusing on therapeutic antibody discovery and leading protein engineering projects (2001-2006). Charlotte completed postdoctoral research in neuronal sodium channel modulation at the University of Washington and holds a doctorate in biochemistry from the University of Leicester, U.K, and an undergraduate degree in biochemistry from the University of Bristol, U.K.